• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » Disease categories and therapies » Respiratory

Respiratory
Respiratory RSS Feed RSS

Lungs

Affibody in $637M respiratory disease deal with Chiesi

March 7, 2023
By Caroline Richards
Chiesi Farmaceutici SpA has agreed to pay Affibody AB up to $214 million in a collaboration and licensing agreement to develop an inhaled treatment for respiratory diseases, with a further $423 million also in the cards if the deal is extended to two more programs. The fees consist of up front and milestone payments, based on certain development, regulatory and commercial achievements, with additional mid-single to low double-digit royalties on sales.
Read More
Lungs and bronchi
Respiratory

PCSK9 blockade lessens airway hyperresponsiveness in obese mice

March 3, 2023
Obesity is tied to airway hyperresponsiveness and lung fibrosis, which may lead to patients with asthma and obesity poorly responding to asthma therapy. Blocking proprotein convertase subtilisin/kexin type 9 (PCSK9) is known to reduce serum cholesterol levels and to exert anti-inflammatory effects.
Read More
Infection

Nebulized mRNA therapy shows promise for pneumonia-induced lung inflammation in preclinical models

March 2, 2023
A new study found that nebulized mRNA therapy could be an effective approach to treating acute respiratory distress syndrome (ARDS), a rapidly progressing lung disease that can lead to respiratory failure and death. This work focused on two genes, nuclear factor kappaB (NF-κB) inhibitor α super-repressor (IκBα-SR) and superoxide dismutase 3 (SOD3), previously shown to reduce the severity of pneumonia when delivered prophylactically by viral vectors.
Read More
Stock merger illustration

Struggling Jounce inks all-share merger deal with Redx

Feb. 23, 2023
By Nuala Moran
Antibody specialist Jounce Therapeutics Inc. and Redx Pharma plc are to merge in an all-share transaction with a value of $425 million, in a deal that will see Redx’s small-molecule cancer and fibrosis drugs absorbing the lion’s share of the combined cash and its shareholders owning 63% of the combined company.
Read More
Drug R&D concept image.
Respiratory

VGLL3 as novel therapeutic target in fibrosis

Feb. 21, 2023
While it is known that differentiated myofibroblasts produce excessive collagens, which accumulate in tissues and cause hardening, the mechanisms involved in these processes are largely unknown. In a recent study, Kyushu University scientists aimed to assess the molecular mechanisms by which matrix stiffness increases fibrosis-related gene expression in myofibroblasts.
Read More
Lungs and bronchi
Respiratory

Rijksuniversiteit Groningen describes new HDAC inhibitors

Feb. 20, 2023
Rijksuniversiteit Groningen has identified histone deacetylase (HDAC) inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, small cell and non-small-cell lung cancer (NSCLC).
Read More
Respiratory

Lung Therapeutics discloses new ENaC blockers

Feb. 2, 2023
Lung Therapeutics Inc. has divulged conjugates comprising epithelial sodium channel (ENaC) blockers (particularly, amiloride and benzamil) covalently linked to peptides to retain in lung tissues reported to be useful for the treatment of cystic fibrosis, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, asthma, primary ciliary dyskinesia, pulmonary emphysema, pneumonia and bronchiectasis.
Read More
Lungs
Respiratory

Discovery of potent STAT3 inhibitor with efficacy in model of IPF

Feb. 2, 2023
Scientists from Sichuan University and affiliated organizations have discovered a new signal transducer and activator of transcription 3 (STAT3) inhibitor, being developed as a potential therapeutic candidate against idiopathic pulmonary fibrosis (IPF).
Read More
Lungs and bronchi

CS Pharma gains Chinese rights to Daewoong’s antifibrotic agent, bersiporocin, in $336M deal

Jan. 31, 2023
By Tamra Sami
Daewoong Pharmaceutical Ltd. has out-licensed greater China rights for its idiopathic pulmonary fibrosis (IPF) candidate, bersiporocin (DWN-2088), to CS Pharmaceuticals Ltd. in a deal worth up to $336 million. Bersiporocin is a prolyl-tRNA synthetase inhibitor being developed by Daewoong for IPF and potentially other fibrotic indications.
Read More
Lungs
Endocrine/Metabolic

CCK/CCKAR signaling identified as a new mechanism in obesity-induced airway hyperresponsiveness

Jan. 24, 2023
Cholecystokinin (CCK) is a peptide hormone found predominantly in the gastrointestinal tract and throughout the central nervous system (CNS), and which has been also shown to stimulate the secretion of calcitonin, insulin and glucagon and to act as a natriuretic kidney peptide. Researchers from Harvard University and affiliated organizations aimed to assess the function of CCK in obesity-induced airway hyperresponsiveness (AHR) and asthma.
Read More
Previous 1 2 … 37 38 39 40 41 42 43 44 45 … 719 720 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 25, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 25, 2025.
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • Gold dollar sign inside gold cog

    Revmed goes global with $2B in capital for RAS(ON) inhibitors

    BioWorld
    Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe